Sangamo Therapeutics Inc (LTS:0R1D)
$ 1.9196 -0.0403 (-2.06%) Market Cap: 417.29 Mil Enterprise Value: 405.82 Mil PE Ratio: 0 PB Ratio: 10.37 GF Score: 34/100

Sangamo Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2019 / 12:00PM GMT
Release Date Price: $10.34
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang. I'm SMID Cap Biotech Analyst. It's my great pleasure to introduce our first speaker Stéphane Boissel, EVP of the Corporate Strategy, to give a presentation; and also with us is McDavid Stilwell, Head of IR and Communication.

StÃ;phane Boissel
Sangamo Therapeutics, Inc. - Executive VP of Corporate Strategy

© -

Thank you, Gena. Well, good morning. My name is Stéphane Boissel. I'm Head of Corporate Strategy at Sangamo. Prior to that, I was the CEO of TxCell, which was sold to Sangamo in the fall.

Before I go through the presentation, I encourage you to read the forward-looking statements. And assuming you've done so, let's move into the presentation, and I will start with a very simple slide. So we like to define ourselves at Sangamo as a genomic medicine company. And when we say that, we are often asked, so what does that mean? That means that we use genomic information from the patient to develop therapies, and we are quite

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot